Transformation of an Inflamed Colon into a Healthy Garden Representing UC Treatment

Could This Chinese Herb Be the Answer to Ulcerative Colitis?

Beau Callahan in Health & Wellness October 2026 • 5 min read.

"New research explores how a pectic polysaccharide from Rauvolfia verticillata could offer a natural way to manage ulcerative colitis symptoms by targeting key inflammatory pathways."

Ulcerative colitis (UC) is a chronic inflammatory condition affecting millions worldwide, characterized by inflammation and ulcers in the colon and rectum. While current treatments offer some relief, they often come with significant side effects and aren't always effective for everyone. This has led researchers to explore alternative, natural therapies that can better manage UC symptoms and improve patients' quality of life.

Traditional Chinese medicine has long utilized herbal remedies for various ailments, including digestive disorders. One such herb, Rauvolfia verticillata, has shown promise due to its potential anti-inflammatory properties. Scientists are now investigating the specific compounds within this herb, particularly a type of complex carbohydrate called pectic polysaccharide (PP), to understand its effects on UC.

This article delves into recent research that examines how pectic polysaccharides extracted from Rauvolfia verticillata can alleviate ulcerative colitis symptoms by modulating key inflammatory pathways in the body. We'll explore the science behind this natural approach and discuss its potential implications for future UC treatments.

Unlocking the Potential of Rauvolfia verticillata: A Natural Approach to UC

Transformation of an Inflamed Colon into a Healthy Garden Representing UC Treatment

A recent study investigated the effects of pectic polysaccharides (PP) extracted from Rauvolfia verticillata on ulcerative colitis (UC) in mice. The research aimed to understand how PP influences the disease and whether it could offer a viable treatment option. Researchers focused on the impact of PP on key inflammatory pathways known as MAPKs and NF-κB, which play a crucial role in the development and progression of UC.

The study divided mice with induced ulcerative colitis into several groups: a control group, a group receiving DSS (to induce UC), a group receiving DSS plus a standard UC medication (SASP), and a group receiving DSS plus the extracted pectic polysaccharides (PP). The researchers then monitored several factors to assess the severity of UC:

Disease Activity Index (DAI): A measure of overall disease severity, including weight loss, stool consistency, and bleeding.
Physical Activity: General activity levels of the mice.
Histological Scores: Microscopic examination of colon tissue to assess inflammation and damage.
Inflammatory Markers: Levels of key inflammatory molecules, such as TNF-α and IL-6.
MAPK and NF-κB Pathways: Activity of these signaling pathways in colon tissue and immune cells.

AI Search Multiple angles on this topic

Latest Research

Microbial Shifts in Ulcerative Colitis

A review of recent advances in ulcerative colitis pathogenesis reports a depletion of protective, short-chain fatty acid-producing bacteria, including Ruminococcaceae and Lachnospiraceae. It also notes an expansion of pro-inflammatory microbes, including Enterobacteriaceae such as Escherichia coli, and Fusobacteriaceae. The review describes these changes as observations associated with the disease, not as evidence that a particular herb reverses them.

Counterpoints

Preclinical Evidence and Its Limits

A study of pectic polysaccharides from Rauvolfia verticillata var. hainanensis reported significant improvement in a murine DSS-induced ulcerative colitis model, linked to regulation of MAPKs and NF-κB pathways in dendritic cells. A separate study proposed that Rauwolfia polysaccharide may affect a UC cell model through a NOS2-mediated JAK2/STAT3 pathway, but explicitly said further studies are warranted. These findings are from animal and cell models, and the latter source presents its mechanism as a supposition rather than a settled conclusion.

Comparison

Herbal Research Versus Established Trial Evidence

The supplied article describes research into pectic polysaccharides extracted from Rauvolfia verticillata and their potential to alleviate ulcerative colitis symptoms by modulating inflammatory pathways. By contrast, the ACG guideline update reports that pivotal trials of etrasimod included patients with isolated proctitis, unlike other modern pivotal trials for moderately to severely active UC. In those etrasimod trials, clinical remission among patients with isolated proctitis was 43.2% at week 12, compared with 13.6% with placebo (P < 0.001); the supplied herb snippet does not provide comparable clinical-trial results.

The results showed that mice treated with PP experienced a significant reduction in UC symptoms. Specifically, the researchers observed: Lower DAI scores, indicating reduced disease severity. Improved physical activity levels. Reduced inflammation and damage in colon tissue. Decreased levels of pro-inflammatory molecules (TNF-α and IL-6). Suppressed activity of the MAPKs and NF-κB inflammatory pathways in both colon tissue and immune cells called dendritic cells (DCs).

Implications and Future Directions

This study provides compelling evidence that pectic polysaccharides from Rauvolfia verticillata offer a promising natural approach to managing ulcerative colitis. By modulating the MAPKs and NF-κB pathways, PP can effectively reduce inflammation and alleviate UC symptoms in mice.

AI Search Multiple angles on this topic

Expert View

Research Questions and Reported Findings

A source dated April 3, 2026, describes an investigation into the effects and underlying mechanisms of pectic polysaccharides isolated from Rauvolfia verticillata. Separately, a study of pectic polysaccharides from Rauvolfia verticillata var. hainanensis reported amelioration of ulcerative colitis and proposed anti-inflammatory effects involving increased expression of IκB proteins and suppression of NF-κB translocation. The supplied 2026 snippet states the study's objective, not its results, so it does not establish what that newer investigation found.

Broader Context

Treatment in a Broader UC Context

A 2026 review summarizes current targeted therapy drug options and signaling pathways associated with ulcerative colitis pathogenesis, aiming to provide a more solid theoretical basis for treatment. A 2022 review outlines key milestones in the history of UC medical management and highlights promising therapeutic developments for the future. Together, these sources frame treatment as a wider field of evolving medical management and targeted approaches, rather than addressing Rauvolfia verticillata specifically.

While these results are encouraging, it's important to note that this research was conducted on animal models. Further studies are needed to confirm the efficacy and safety of PP in human patients with UC. Clinical trials will be crucial to determine the optimal dosage, delivery method, and potential side effects of this natural compound.

If future research confirms these findings, pectic polysaccharides from Rauvolfia verticillata could represent a valuable addition to the UC treatment landscape, offering a more natural and potentially less harmful alternative to existing medications. This could significantly improve the lives of individuals struggling with this chronic inflammatory condition.

Curcumin results depend on the outcome and analysis

OR 5.83; OR 4.33In a per-protocol analysis, curcumin was associated with higher odds of clinical remission than placebo (OR 5.83, 95% CI 1.24–27.43); the intention-to-treat analysis did not show a statistically significant difference (OR 4.33, 95% CI 0.78–24.00).^[1]Caveat: The per-protocol result was significant, but the intention-to-treat result was not.

Herbal findings alongside other UC evidence

The broader rationale for studying pyroptosis is that inflammatory caspases can trigger it and produce pro-inflammatory cytokines; suppressing pyroptosis has also been reported to lessen experimental colitis damage. This background makes pyroptosis a plausible research focus, not proof that the herb works by suppressing it.^[2]

JAK2/STAT3 is described as an inflammation-related signaling pathway involved in cytokine production and recruitment or activation. That context helps explain why it was proposed in a cell-model account, but does not confirm the proposed mechanism.^[3]

Other herbal research has evaluated curcumin combined with QingDai in active ulcerative colitis, and curcumin is described as a complementary therapy intended to ease symptoms and maintain remission. These examples show that herbal research spans different preparations and evidence types; they do not establish the efficacy of Rauvolfia polysaccharides in people.^{[1] [4]}

What remains unresolved about Rauvolfia polysaccharides

Does the proposed NOS2-mediated JAK2/STAT3 account hold up beyond the cell model? The source frames it as a supposition that still requires testing.^[3]

Terms behind the proposed pathways

Pyroptosis: A process that can be induced by activated inflammatory caspases, which also produce pro-inflammatory cytokines.^[2]
DSS colitis model: An experimental colitis model whose many influencing factors can affect study quality, interpretation, and translation.^[5]

Sources

Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (pmc.ncbi.nlm.nih.gov)
Pectic polysaccharides ameliorate the pathology of ulcerative colitis in mice by reducing pyroptosis (pmc.ncbi.nlm.nih.gov)
Rauwolfia polysaccharide can inhibit the progress of ulcerative colitis through NOS2-mediated JAK2/STAT3 pathway (pmc.ncbi.nlm.nih.gov)
Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial. (pubmed.ncbi.nlm.nih.gov)
DSS Colitis Model: Traps, Tricks, and Reporting Recommendations (pmc.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

How can pectic polysaccharides from Rauvolfia verticillata help with ulcerative colitis?

Research indicates that pectic polysaccharides derived from Rauvolfia verticillata can alleviate ulcerative colitis symptoms by modulating inflammatory pathways, specifically the MAPKs and NF-κB pathways. This modulation reduces inflammation and damage in colon tissue, leading to decreased disease severity.

2

What key indicators were used to assess the severity of ulcerative colitis in the study?

The study assessed the severity of ulcerative colitis using several key indicators: the Disease Activity Index (DAI), which measures overall disease severity; physical activity levels of the mice; histological scores from microscopic examination of colon tissue; levels of inflammatory markers like TNF-α and IL-6; and the activity of the MAPKs and NF-κB pathways in colon tissue and immune cells.

3

What were the specific results observed in mice treated with pectic polysaccharides from Rauvolfia verticillata?

The study showed that pectic polysaccharides extracted from Rauvolfia verticillata significantly reduced ulcerative colitis symptoms in mice. This was evidenced by lower DAI scores, improved physical activity levels, reduced inflammation and damage in colon tissue, decreased levels of pro-inflammatory molecules (TNF-α and IL-6), and suppressed activity of the MAPKs and NF-κB inflammatory pathways in colon tissue and dendritic cells.

4

Why are the MAPKs and NF-κB pathways important in understanding the effects of Rauvolfia verticillata on ulcerative colitis?

MAPKs and NF-κB are key inflammatory pathways involved in the development and progression of ulcerative colitis. By modulating these pathways, pectic polysaccharides from Rauvolfia verticillata can effectively reduce inflammation and alleviate UC symptoms. The NF-kB pathway is a transcription factor that induces the expression of pro-inflammatory cytokines. The Mitogen-activated protein kinases (MAPKs) are a family of protein kinases that are activated in response to various stimuli, such as growth factors, cytokines, and stress. Activation of the MAPK pathway leads to the production of inflammatory mediators.

5

What are the next steps in researching pectic polysaccharides from Rauvolfia verticillata as a potential treatment for ulcerative colitis?

While the study demonstrates promising results in mice, further research is needed to determine the efficacy and safety of using pectic polysaccharides from Rauvolfia verticillata to treat ulcerative colitis in humans. Future studies should focus on clinical trials to evaluate the potential benefits and risks of this natural approach for managing UC symptoms in human patients. It would be interesting to see if similar effects could be found in humans and how it compares to existing treatments.